This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effects of PGI2 Analogue Use on the Development of Chronic Allograft Nephropathy

This study has been completed.
Information provided by (Responsible Party):
Jongwon Ha, Seoul National University Hospital Identifier:
First received: January 24, 2010
Last updated: May 24, 2015
Last verified: May 2015
The purpose of this study is to evaluate the effect of Prostaglandin I2 analogue use on the development of chronic allograft nephropathy and changes in allograft function in prevalent renal transplant recipients

Condition Intervention Phase
Chronic Allograft Nephropathy Drug: prostaglandin I2 analogue Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Effects of PGI2 Analogue Use on the Development of Chronic Allograft Nephropathy

Resource links provided by NLM:

Further study details as provided by Jongwon Ha, Seoul National University Hospital:

Primary Outcome Measures:
  • graft pathology, serum creatinine, creatinine clearance, eGFR [ Time Frame: 1 year after drug administration ]

Estimated Enrollment: 40
Study Start Date: June 2009
Study Completion Date: June 2014
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: control Drug: prostaglandin I2 analogue


Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • prevalent renal transplant recipients 2 years after transplantation
  • no history of acute rejection
  • stable renal function

Exclusion Criteria:

  • history of biopsy-proven chronic allograft nephropathy
  • history of biopsy-proven CNI nephrotoxicity
  • history of biopsy-proven or clinical acute rejection
  • unstable trough level of CNI or extremely low level of CNI
  • bleeding tendency(+)
  • pregnancy or pregnant-willing
  • anticoagulation(+)
  • antiplatelet agent (+)
  • significant comorbidity(+): Acute coronary syndrome, pneumonia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01056835

Korea, Republic of
Seoul National University Hospital
Seoul, Korea, Republic of, 110-744
Sponsors and Collaborators
Seoul National University Hospital
Principal Investigator: Jongwon Ha, MD, PhD Seoul National University
  More Information

Responsible Party: Jongwon Ha, Professor, Seoul National University Hospital Identifier: NCT01056835     History of Changes
Other Study ID Numbers: Beraprost-01
Study First Received: January 24, 2010
Last Updated: May 24, 2015

Additional relevant MeSH terms:
Kidney Diseases
Urologic Diseases
Antihypertensive Agents
Platelet Aggregation Inhibitors
Vasodilator Agents processed this record on September 21, 2017